Treating T2DM and obesity with bariatric surgery and GLP1 agents

Nature Reviews Endocrinology

Volumn 15, Issue 9, 2019, Pages 504-506

  Bailey, Clifford J ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; METFORMIN; SULFONYLUREA;

ALZHEIMER DISEASE; BARIATRIC SURGERY; BLOOD PRESSURE REGULATION; BODY WEIGHT LOSS; CALORIC INTAKE; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FOLLOW UP; GLUCAGON RELEASE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INCIDENCE; INSULIN RELEASE; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; ROUX-EN-Y GASTRIC BYPASS; SLEEVE GASTRECTOMY; STOMACH MOTILITY; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 85070328304     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/s41574-019-0240-4     Document Type: Note

References (10)

1. Rubino, F. et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care. 39, 861–877 (2016).
2. Schauer, P. R. et al. Bariatric surgery versus intensive medical therapy for diabetes — 5-year outcomes. N. Engl. J. Med. 376, 641–651 (2017).
3. Adams, T. D. et al. Weight and metabolic outcomes 12 years after gastric bypass. N. Engl. J. Med. 377, 1143–1155 (2017).
4. Steinert, R. E. et al. Ghrelin, CCK, GLP-1, and PYY(3–36): secretory controls and physiological roles in eating and glycemia in health, obesity, and after RYGB. Physiol. Rev. 97, 411–463 (2017).
5. Nannipieri, M. et al. Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones. J. Clin. Endocrinol. Metab. 98, 4391–4399 (2013).
6. Hutch, C. R. & Sandoval, D. The role of GLP-1 in the metabolic success of bariatric surgery. Endocrinology 158, 4139–4151 (2017).
7. Lim, S., Kim, K. M. & Nauck, M. A. Glucagon-like peptide-1 receptor agonists and cardiovascular events: class effects versus individual patterns. Trends Endocrinol. Metab. 29, 238–248 (2018).
8. Bailey, C. J. & Marx, N. Cardiovascular protection in type 2 diabetes: insights from recent outcome trials. Diabetes Obes. Metab. 21, 3–14 (2019).
9. Gorgojo-Martínez, J. J., Feo-Ortega, G. & Serrano-Moreno, C. Effectiveness and tolerability of liraglutide in patients with type 2 diabetes mellitus and obesity after bariatric surgery. Surg. Obes. Relat. Dis. 12, 1856–1863 (2016).
10. Miras, A. D. et al. Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 10.1016/S2213-8587(19)30157-3 (2019).